Ranbaxy-Teva Atorvastatin Mystery Deal Decoded: Many Likely Scenarios Aimed At “On Time” Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry sources tell PharmAsia News that Ranbaxy forged the Teva Lipitor deal as a back-up plan, one that could prove costly for Ranbaxy.